FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Five Prime Therapeutics Shares Rise on Positive Cancer Trial Results”
Five Prime Therapeutics (NASDAQ: FPRX) shot up 321% in premarket trading after the company said its treatment for gastric cancer met all three of its efficacy endpoints from its Phase 2 trial.
Bemarituzumab is a potential first-in-class therapeutic antibody targeting specific tumors found in about 30% of HER2- gastric cancers worldwide, and findings have shown additional potential areas for development of the drug beyond gastric and GEJ cancer.
Five Prime Therapeutics, Inc. discovers and develops innovative protein therapeutics to improve the lives of patients with serious diseases. Five Prime’s product candidates have innovative mechanisms of action and address patient populations in need of better therapies. The company focuses on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates.
For more information, please visit: Five Prime Therapeutics, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.